Melissa M. Ronan

This study identifies RAS(ON) inhibitors effective against NRAS-mutated melanoma and reveals resistance mechanisms through Ppia and Map2k1 mutations.

This study shows that degrading p300/CBP in prostate cancer suppresses tumor growth more effectively than inhibiting their activity, highlighting their role in maintaining the active AR enhanceosome.

This study shows CDK11 is critical for cancer cell survival and identifies 1p36 deletions as a biomarker for CDK11 inhibitor sensitivity, but on-target toxicity limits therapeutic efficacy.

This study identifies DNA hypomethylation, not DNA damage, as the primary mechanism of azacytidine and decitabine anti-cancer activity, linking it to chromatin regulators like USP48.

The paper identifies genetic vulnerabilities linked to transcription factor activities in cancer cell lines using CRISPR knockout data and validates targets associated with TEAD1.

This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.